Back to top
more

Cognyte Software (CGNT)

(Real Time Quote from BATS)

$7.80 USD

7.80
107,249

+0.06 (0.78%)

Updated Jul 15, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Internet - Software

Better trading starts here.

Zacks News

Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

    Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?

    Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.

      4 Growth Stocks to Pick From a Choppy MedTech Market

      In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.

        Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher

        Cogentix Medical (CGNT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.

          AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1

          AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.

            Masimo RAS-45 Full-Market Release to Boost Respiratory Care

            Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.

              Baxter Announces Launch of DeviceVue System for Sigma Pumps

              Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.

                ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern

                ABIOMED (ABMD) is focusing heavily in its proprietary Impella Platform to enhance customer base.

                  Allscripts Rides High on Product Launches Amid Rising Costs

                  Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.

                    Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                    Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.

                      Here's Why Investors Should Buy Masimo (MASI) Right Now

                      Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.

                        BD (BDX) Inks New Deal to Strengthen Foothold in STI Space

                        BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.

                          Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance

                          Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.

                            Varian Conducts Clinical Workshop, Strengthens Algeria Hold

                            Varian (VAR) has 30 systems operating in Algeria at the moment. The latest development signifies the company's long-term goal of serving six million cancer patients every year.

                              AngioDynamics' BioFlo Platform Strong, Debt Levels High

                              AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.

                                Allscripts' Latest Initiative Eradicates Price Ambiguity

                                Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.

                                  DaVita's (DVA) Green Initiatives Win a Coveted Golden Reward

                                  DaVita's (DVA) environment-friendly operations are likely to enhance the company's long-term sustainable growth. Also, strong patient services drive DaVita's success story.

                                    Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?

                                    Baxter (BAX) reaches a 52-week high on the back of an impressive product line. Buoyed by last quarter's stellar growth in earnings and sales, the company also raises long-term outlook.

                                      Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?

                                      Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.

                                        The Cooper Companies (COO) Beats Earnings Estimates in Q3

                                        The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.

                                          NxStage System One Gets FDA Nod for Solo Home Hemodialysis

                                          The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.

                                            Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash

                                            Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash

                                              Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates

                                              Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.

                                                Swarup Gupta headshot

                                                5 Bargain Breakout Stocks Offering Stunning Returns

                                                The key to this kind of stock selection is to identify players that are trading within a narrow band.

                                                  Stryker Recalls Sage Unit Products, Guidance Takes a Hit

                                                  Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.